Validation of the OncoDEEP® Kit comprehensive genomic panel on the MGI platform

Introduction :

This study aims to compare tumour characterization using the OncoDEEP® Kit end-to-end solution with an MGI sequencer as an alternative to Illumina technology. The validation results demonstrate that the MGI platform, by generating high-quality data, represents an excellent alternative, with all variant and fusion detections being comparable. Furthermore, the correlation of genomic signatures using data from MGI sequencing shows a high concordance with Illumina. Explore this poster to discover why MGI technology might be considered a cost-effective alternative to Illumina technology.

You may also be interested in these resources

Scientific Application Note

BREAST CANCER Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Abstract PURPOSE: The activating mutation AKT1E17K occurs in approximately 7% of estrogen receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study, tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy...

Share This